Oxford Biomedica Solutions
Thomas Thiers has extensive experience in the biotechnology and biomedical fields, currently serving as a Scientist at Oxford Biomedica Solutions since March 2022 and as a Research Associate at Homology Medicines, Inc. since November 2017. Prior to these roles, Thomas held various positions at Genocea Biosciences, starting as a Development Intern in 2013 and advancing to Development Associate I, II, and III from March 2015 to September 2017. Thomas holds a Master of Arts degree in Classics from Boston College and an Associate of Science degree in Biotechnology Technician from Middlesex Community College.
Oxford Biomedica Solutions
Oxford Biomedica Solutions, LLC is the high-performing, full scope Adeno-Associated Virus (AAV) vector Manufacturing and Innovation joint venture of Oxford Biomedica plc (LSE:OXB) (“Oxford Biomedica” or “the Group”), and Homology Medicines, Inc. (Nasdaq: FIXX) (“Homology”). We offer global pharmaceutical and biotechnology clients innovative manufacturing expertise in AAV and lentiviral-based cell and gene therapies. Oxford Biomedica Solutions LLC provides access to Homology’s innovative and proven end-to-end AAV manufacturing capabilities, and customers also benefit from technical synergies brought in by the Group’s know-how in lentiviral vector manufacturing. This collaborative and complementary vector-based approach has the potential to accelerate our collective mission to improve patients’ lives worldwide.